Synthetic aminoindanes: a summary of existing knowledge
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F17%3A43919035" target="_blank" >RIV/00023752:_____/17:43919035 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/17:43915969
Result on the web
<a href="https://www.frontiersin.org/articles/10.3389/fpsyt.2017.00236/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fpsyt.2017.00236/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fpsyt.2017.00236" target="_blank" >10.3389/fpsyt.2017.00236</a>
Alternative languages
Result language
angličtina
Original language name
Synthetic aminoindanes: a summary of existing knowledge
Original language description
Objectives: Aminoindanes (“bath salts”, a class of novel psychoactive substances, NPSs) increased rapidly in popularity on the recreational drug market, particularly after mephedrone and other synthetic cathinones were banned in the UK in 2010. Novel aminoindanes continue to emerge, but relatively little is known about their effects and risks. Their history, chemistry, pharmacology, behavioural effects, pharmacokinetics and toxicity are reviewed in this paper. Methods: Scientific literature was searched on ISI Web of Knowledge: Web of Science (WoS) during June and July 2017, using English language terms: aminoindane, MDAI, 5,6-methylenedioxy-2-aminoindane, 5-IAI, 5-Iodo-2-aminoindane, 2-aminoindane, MDMAI, 5,6-Methylenedioxy-N-methyl-2-aminoindane, MMAI, 5-Methoxy-6-methyl-2-aminoindane. WoS was selected as it searches several databases simultaneously and has quality criteria for inclusion. For typical use and effects Erowid, PsychonautWiki, Bluelight and Drugs-Forum were searched; for legal status and epidemiology, the European Information System and Database on New Drugs (EDND) was used. Results: Aminoindanes were first synthesized for medical use as e.g., as anti-Parkinsonian drugs and later as a potential compound facilitating psychotherapy, however they are now widely substituted for ecstasy. Their mechanisms of action (primarily via serotonin), mean that they may pose a significant risk of serotonin syndrome at high doses, or when combined with other drugs. Fatally toxic effects have been observed both in the laboratory in animal studies and in clinic, where aminoindanes-related deaths have been reported. Conclusion: Greater knowledge about aminoindanes is urgently required to decrease risks of fatal intoxication, and appropriate legislation is needed to protect public health without impeding research.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30215 - Psychiatry
Result continuities
Project
<a href="/en/project/LO1611" target="_blank" >LO1611: Sustainability for The National Institute of Mental Health</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Psychiatry
ISSN
1664-0640
e-ISSN
—
Volume of the periodical
8
Issue of the periodical within the volume
November
Country of publishing house
CH - SWITZERLAND
Number of pages
7
Pages from-to
"Article Number: 236"
UT code for WoS article
000415593400001
EID of the result in the Scopus database
2-s2.0-85034572487